Michael Nace

Dec 13, 2023 | brnw.ch | Michael Nace

From landmark gene therapy approvals to illuminating discoveries into the pathogenesis of rare diseases, 2023 saw substantive advances in rare disease diagnosis and treatment. The following list of articles represents the most-read stories on Rare Disease Advisor throughout the year:The US Food and Drug Administration (FDA) approved the first gene therapy for Duchenne muscular dystrophy (DMD), for the treatment of children with the disease who are 4 to 5 years of age and still able to walk.

Dec 13, 2023 | rarediseaseadvisor.com | Michael Nace

From landmark gene therapy approvals to illuminating discoveries into the pathogenesis of rare diseases, 2023 saw substantive advances in rare disease diagnosis and treatment. The following list of articles represents the most-read stories on Rare Disease Advisor throughout the year:The US Food and Drug Administration (FDA) approved the first gene therapy for Duchenne muscular dystrophy (DMD), for the treatment of children with the disease who are 4 to 5 years of age and still able to walk.

May 6, 2020 | prostatecancernewstoday.com | Michael Nace

May 6, 2020 | copdnewstoday.com | Michael Nace

May 5, 2020 | huntingtonsdiseasenews.com | Michael Nace